Literature DB >> 10762657

Fate of 2-deoxy-2-[18F]fluoro-D-glucose in control and diabetic rats.

W J Malaisse1, P Damhaut, F Malaisse-Lagae, L Ladriere, E Olivares, S Goldman.   

Abstract

Recent experiments conducted in vitro have documented a marked difference in the time course for D-[U-14C]glucose net uptake by pieces of pancreatic tissue versus isolated pancreatic islets. The present study aimed, therefore, at assessing whether the endocrine pancreas contributes to a detectable extent to the overall net uptake of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) by the pancreatic gland. For this purpose, the radioactive content of the pancreas was compared to that of plasma, erythrocytes, liver, brain, hypophysis and parotid gland 3 min, 15 min and 240 min after the intravenous injection of FDG to both control rats and animals injected with streptozotocin and later treated with insulin or not. In the control rats, the radioactive content (cpm/mg wet wt.) of erythrocytes was always lower than that of liver. In other organs, it displayed the following hierarchy pancreas < parotid < hypophysis < brain, the absolute values being either lower (3 min) or much higher (240 min) than in liver. In the diabetic rats, whether treated with insulin or not, the radioactive content of erythrocytes, pancreas, brain, hypophysis and parotid gland, relative to the paired value found in liver, was equal or lower than that of control rats when the animals were hyperglycemic and equal or higher than that of control rats when the animals became hypoglycemic as the result of intensive insulin treatment. Even only 3 min after the injection of FDG, and despite persistent hyperglycemia in the streptozotocin-injected and insulin-treated rats, the pancreas/ liver paired ratio in radioactive content failed to be significantly lower in the diabetic animals than in control rats. These findings indicate that 2-deoxy-2-[18F]fluoro-D-glucose is not a suitable tool to detect any preferential labelling of insulin-producing cells, relative to acinar cells, at least when considering only the total radioactive content of the pancreatic gland.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762657     DOI: 10.3892/ijmm.5.5.525

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Labeling of pancreatic glycogen by D-[U-14c]glucose in hyperglycemic rats.

Authors:  L Ladrière; K Louchami; A Laghmich; F Malaisse-Lagae; W J Malaisse
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

3.  Pancreatic fate of 6-deoxy-6-[125I]iodo-D-glucose: in vitro experiments.

Authors:  W J Malaisse; L Ladrière; A Sener
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

Review 4.  Advances in beta-cell imaging.

Authors:  Anna Moore
Journal:  Eur J Radiol       Date:  2009-03-03       Impact factor: 3.528

5.  Advances in molecular imaging of pancreatic beta cells.

Authors:  Mai Lin; Angelo Lubag; Michael J McGuire; Serguei Y Seliounine; Edward N Tsyganov; Peter P Antich; A Dean Sherry; Kathlynn C Brown; Xiankai Sun
Journal:  Front Biosci       Date:  2008-05-01

6.  PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?

Authors:  Andor W J M Glaudemans; Ana Maria Quintero; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05       Impact factor: 9.236

Review 7.  Targets and probes for non-invasive imaging of β-cells.

Authors:  Andreas Jodal; Roger Schibli; Martin Béhé
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-26       Impact factor: 9.236

8.  Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.

Authors:  Stefanie M A Willekens; Lieke Joosten; Otto C Boerman; Alexander Balhuizen; Decio L Eizirik; Martin Gotthardt; Maarten Brom
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.